In patients with COVID-19 at risk for severe disease, nirmatrelvir + ritonavir reduced hospitalization or death.
Where this comes from
- Record sourced from PubMed, PMID 35667068.
- Also identified by DOI 10.7326/J22-0038.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hammond J, Leister-Tebbe H, Gardner A, et al. <b>Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19.</b> N Engl J Med. 2022;386:1397-408. 35172054.
Medical subject headings
- COVID-19 Drug Treatment